ACORQ — Acorda Therapeutics Share Price
0.000.00%
Last trade - 00:00- $0.02m
- $182.13m
- $117.63m
- 41
- 63
- 17
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -236.12% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 192.41 | 152.97 | 129.07 | 118.57 | 117.63 | n/a | n/a | -24.24% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.
Directors
- John Kelley NEC (67)
- Ron Cohen CEO (65)
- Michael Gesser CFO (59)
- Lauren Sabella COO (60)
- Neil Belloff GCN (62)
- Kerry Clem OTH
- John Varian DRC (58)
- Peder Jensen IND (66)
- Sandra Panem IND (74)
- Lorin Randall IND (77)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- March 17th, 1995
- Public Since
- February 10th, 2006
- No. of Shareholders
- 10
- No. of Employees
- 102
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 1,242,098
- Address
- TWO BLUE HILL PLAZA, PEARL RIVER, 10965
- Web
- https://www.acorda.com
- Phone
- +1 9143474300
- Auditors
- Ernst & Young LLP
Upcoming Events for ACORQ
Similar to ACORQ
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Acorda Therapeutics share price?
As of Today at 22:58 UTC, shares in Acorda Therapeutics are trading at $0.01. This share price information is delayed by 15 minutes.
How has the Acorda Therapeutics share price performed this year?
Shares in Acorda Therapeutics last closed at $0.01 and the price had moved by -99.92% over the past 365 days. In terms of relative price strength the Acorda Therapeutics share price has underperformed the S&P500 Index by -99.94% over the past year.
What are the analyst and broker recommendations for Acorda Therapeutics?
The overall consensus recommendation for Acorda Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Acorda Therapeutics dividend yield?
Acorda Therapeutics does not currently pay a dividend.
Does Acorda Therapeutics pay a dividend?
Acorda Therapeutics does not currently pay a dividend.
When does Acorda Therapeutics next pay dividends?
Acorda Therapeutics does not currently pay a dividend.
How do I buy Acorda Therapeutics shares?
To buy shares in Acorda Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Acorda Therapeutics?
As of the previous close price of $0.01, shares in Acorda Therapeutics had a market capitalisation of $0.02m.
Where are Acorda Therapeutics shares listed?
Here are the trading details for Acorda Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ACORQ
What kind of share is Acorda Therapeutics?
Based on an overall assessment of its quality, value and momentum Acorda Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Acorda Therapeutics share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Acorda Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acorda Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -99.91%.
As of the last closing price of $0.01, shares in Acorda Therapeutics were trading -99.82% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Acorda Therapeutics PE Ratio?
The Acorda Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Acorda Therapeutics?
Acorda Therapeutics' management team is headed by:
- John Kelley - NEC
- Ron Cohen - CEO
- Michael Gesser - CFO
- Lauren Sabella - COO
- Neil Belloff - GCN
- Kerry Clem - OTH
- John Varian - DRC
- Peder Jensen - IND
- Sandra Panem - IND
- Lorin Randall - IND